Search | Clinical Trials Finder

Conditions: Prostate Cancer
Interventions: myocardial PET imaging; Device
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 51 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Civasheet 60 Gy, Civasheet 75 Gy, Adjuvant external beam radiation therapy; Radiation
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: computed tomography, ultrasound imaging; Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Androgen Axis Suppression, Prostatectomy, Prostate Cancer
Interventions: Apalutamide, Androgen Deprivation Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Gilbert, Arizona • Chicago, Illinois • Kansas City, Kansas + 3 more

Conditions: Prostate Cancer
Interventions: 3D-CRT; Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,084 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2013
U.S. locations: 213
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more

Conditions: Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Abiraterone Acetate, Bicalutamide, Biospecimen Collection, Computed Tomography Angiography, Leuprolide, Prednisone, Radiation Therapy, Relugolix; Drug · Procedure · Radiation
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Over-Active Bladder
Interventions: Solifenacin succinate, Placebo; Drug
Lead sponsor: Advanced Research Network; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Ga-68 labeled HBED-CC PSMA, Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT), Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI); Drug · Device
Lead sponsor: Thomas Hope; Other
Eligibility: 18 Years and older · Male only
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer, Adenocarcinoma of the Prostate
Interventions: Brachytherapy; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Prostatic Neoplasms
Interventions: Amifostine trihydrate, Radiation therapy; Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bone Metastases, Multiple Myeloma
Interventions: ExAblate MRfFUS, Sham; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: La Jolla, California • Stanford, California • Boca Raton, Florida + 5 more

Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Melanoma
Interventions: SBRT, IMRT, Brachytherapy; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Transperineal Ultrasound; Device
Lead sponsor: H. James Wallace, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: U.S. Army Medical Research Acquisition Activity; Federal
Eligibility: 40 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Prostate Cancer
Interventions: ARN-509, Abiraterone, Leuprolide, stereotactic, ultra-fractionated radiotherapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 11
States / cities: Baltimore, Maryland • Ann Arbor, Michigan • Middletown, New Jersey + 7 more

Conditions: Prostate Cancer
Interventions: docetaxel, leuprolide acetate, radiation therapy; Drug · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Raleigh, North Carolina

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Cancer (Adenocarcinoma)
Interventions: Brachytherapy; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 40 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts

Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions: Internal Radiation Therapy, Bicalutamide, Leuprolide Acetate, Goserelin Acetate, Triptorelin Pamoate, Degarelix, Laboratory Biomarker Analysis, Quality-of-Life Assessment; Radiation · Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: Male only
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Prostate Carcinoma
Interventions: Biospecimen Collection; Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 50 Years to 79 Years · Male only
Enrollment: 810 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: bevacizumab, bicalutamide and goserelin, intensity modulated radiation therapy (IMRT); Drug · Procedure
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: Questioners, blood specimens, prostate tissue specimens; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 35 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Search by objective public record fields.

Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy

CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation

Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound

Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer

ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy

The Use of Transperineal Ultrasound for Radiation Therapy Treatment Planning and Image Guidance in the Treatment of Prostate Cancer

Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)

Daily Target Guided Radiation Therapy Using the Calypso 4D Localization System in Patients Who Have Had a Prostatectomy for Prostate Cancer

AASUR in High Risk Prostate Cancer

Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer

Assessment of 3D Transperineal Ultrasound Imaging w/ Matrix Array Transducers in Prostate Radiotherapy

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)

Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer

Prostate Biomarker Study